Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Financial Close For Primary Care Project

18 Nov 2010 07:00

RNS Number : 3741W
CareCapital Group plc
18 November 2010
 



18 November 2010

 

CARECAPITAL GROUP PLC

("CareCapital" or "the Company")

 

Financial Close for Primary Care Project in West Wirral

 

CareCapital Group Plc is pleased to announce that it has completed the agreements with the tenants, funder and construction contractor to enable it to proceed with the development of its 2,000 Sq m primary care project in Thingwall, West Wirral.

 

The Project, costing £4.5 million, comprises a medical centre; community health clinics and a pharmacy; and will be fully financed through a forward funding and sale agreement with MedicX, a listed fund specialising in long term investment in primary care real estate in the UK.

 

Construction works will start at the end of November with a contract completion target of November 2011.

 

This development is part of CareCapital's current project pipeline of 9 developments in the UK and 2 in Germany.

 

 

For further information please visit www.carecapital.co.uk or contact:

 

CareCapital Group Plc

Daniel Stewart & Co. Plc

Tavistock Communications

Paul Stacey, Chief Executive

Oliver Rigby

Simon Hudson

 

Tel: 020 7034 1949

Tel: 020 7776 6550

Tel: 020 7920 3150

pstacey@carecapital.co.uk

oliverr@danielstewart.co.uk

shudson@tavistock.co.uk

 

 

~ ends ~

 

 

Notes to Editors

 

CareCapital is a developer and investor in primary healthcare real estate, partnering GPs, dentists and other clinical providers - in the UK and Germany - to develop uniquely tailored, cost-effective and sustainable care facilities. CareCapital has a current portfolio value of £39.9 million (as at 31 December 2007).

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREAKFXFDLEFFF
Date   Source Headline
30th Oct 20205:00 pmRNSTotal Voting Rights
26th Oct 20207:00 amRNSEquity fundraise of c.£7.7m
23rd Oct 20202:25 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy: Progress towards commissioning of first LIGHT
19th Oct 20207:00 amRNSInvestor Day Update
8th Oct 20202:06 pmRNSSecond Price Monitoring Extn
8th Oct 20202:00 pmRNSPrice Monitoring Extension
7th Oct 202010:50 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Progress towards commissioning of first LIGHT
6th Oct 20207:00 amRNSReplacement: Grant of LTIP Options
5th Oct 20207:01 amRNSNotice of Investor Day
5th Oct 20207:00 amRNSGrant of LTIP Options
29th Sep 20207:00 amRNSDirectorate Appointment
29th Sep 20207:00 amRNSInterim Results
8th Sep 20207:00 amRNSTechnical Development Update
7th Sep 20207:00 amRNSAppointment of Joint Broker
21st Aug 20207:00 amRNSDraw down from Nerano Pharma debt facility
18th Aug 20204:30 pmRNSDirector/PDMR Shareholding
29th Jul 20202:52 pmRNSResult of AGM and Directorate Changes
2nd Jul 20207:15 amEQSHardman & Co Research : Advanced Oncotherapy (AVO): End-goal fast approaching
29th Jun 20207:01 amRNSFinal Results for the year ended 31 December 2019
29th Jun 20207:00 amRNSStrategic funding partnership and debt facility
17th Jun 20207:00 amRNSHolding(s) in Company
8th Jun 20207:00 amRNSDirectorate Changes and Notice of Results
3rd Jun 20205:30 pmRNSHolding(s) in Company
29th May 20205:00 pmRNSTotal Voting Rights
20th May 20204:30 pmRNSHolding(s) in Company
11th May 20206:01 pmRNSResult of General Meeting, Additional Subscription
21st Apr 20207:00 amRNSNotice of GM and Posting of Circular
9th Apr 20207:30 amRNSFurther re Subscription and Issue of Equity
9th Apr 20207:00 amRNSProposed Subscription to raise c.£15 million
26th Feb 20203:40 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
17th Feb 202011:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
17th Feb 20207:00 amRNSPurchase of a LIGHT proton therapy system
11th Feb 20207:00 amRNSPartnership with The London Clinic
4th Dec 20197:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Proving the accuracy and superiority of minibeams
4th Dec 20197:00 amRNSTwo-Year Collaborative Research Study
3rd Dec 20195:45 pmRNSHolding(s) in Company
29th Nov 20195:00 pmRNSTotal Voting Rights
28th Nov 201910:15 amRNSHolding(s) in Company
20th Nov 20197:00 amRNSSubscription to raise c.GBP 2.7 million
11th Nov 20199:11 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): FLASH benefits from new US reimbursement
6th Nov 20193:35 pmRNSTotal Voting Rights
10th Oct 20197:00 amRNSChange of Broker
30th Sep 20195:15 pmRNSTotal Voting Rights
30th Sep 20197:00 amRNSFurther re funding for first LIGHT system
30th Sep 20197:00 amRNSHalf-year Report
9th Sep 20194:48 pmRNSExercise of Warrants and Issue of Equity
30th Aug 20195:00 pmRNSTotal Voting Rights
29th Aug 20192:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.